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Abstract
Fasting in human subjects shifts skeletal muscle metabolism toward lipid utilization and 
accumulation, including intramyocellular lipid (IMCL) deposition. Growth hormone 
(GH) secretion amplifies during fasting and promotes lipolysis and lipid oxidation, but 
it is unknown to which degree lipid deposition and metabolism in skeletal muscle dur-
ing fasting depends on GH action. To test this, we studied nine obese but otherwise 
healthy men thrice: (a) in the postabsorptive state (“CTRL”), (b) during 72‐hr fasting 
(“FAST”), and (c) during 72‐hr fasting and treatment with a GH antagonist (GHA) 
(“FAST + GHA”). IMCL was assessed by magnetic resonance spectroscopy (MRS) and 
blood samples were drawn for plasma metabolomics assessment while muscle biopsies 
were obtained for measurements of regulators of substrate metabolism. Prolonged fasting 
was associated with elevated GH levels and a pronounced GHA‐independent increase 
in circulating medium‐ and long‐chain fatty acids, glycerol, and ketone bodies indicat-
ing increased supply of lipid intermediates to skeletal muscle. Additionally, fasting was 
associated with a release of short‐, medium‐, and long‐chain acylcarnitines to the circula-
tion from an increased β‐oxidation. This was consistent with a ≈55%–60% decrease in 
pyruvate dehydrogenase (PDHa) activity. Opposite, IMCL content increased ≈75% with 
prolonged fasting without an effect of GHA. We suggest that prolonged fasting increases 
lipid uptake in skeletal muscle and saturates lipid oxidation, both favoring IMCL deposi-
tion. This occurs without a detectable effect of GHA on skeletal muscle lipid metabolism.
K E Y W O R D S
fasting, Growth hormone, intramyocellular lipid, pyruvate dehydrogenase activity, skeletal muscle
1 |  INTRODUCTION
Skeletal muscle metabolism is a major determinant of over-
all resting energy expenditure (Zurlo, Larson, Bogardus, 
& Ravussin, 1990) and is able to rapidly shift between 
carbohydrate and fat oxidation (Kelley, Goodpaster, Wing, & 
Simoneau, 1999). It is estimated that skeletal muscle accounts 
for up to 85% of glucose uptake during an hyper‐insulinemic 
euglycemic insulin clamp (DeFronzo et al., 1981), whereas 
only ≈25% of an oral glucose load is disposed in muscle 
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tissue. During prolonged fasting, however, the sensitivity to 
insulin in skeletal muscle is profoundly reduced (Vendelbo 
et al., 2012), which increases the availability of glucose for 
oxidation in other tissues such as the brain. Reduced sensi-
tivity to insulin in skeletal muscle is also a pathophysiolog-
ical hallmark of type 2 diabetes, and insulin resistance is an 
early predictor of this disease (Warram, Martin, Krolewski, 
Soeldner, & Kahn, 1990).
Growth hormone (GH) is an important regulator of sub-
strate metabolism and insulin sensitivity in skeletal mus-
cle (Nellemann et al., 2014). GH treatment reduces overall 
fat mass (FM) through lipolytic actions in adipose tissues 
(Salomon, Cuneo, Hesp, & Sonksen, 1989) and decreased 
adipose tissue triacylglycerol (TAG) synthesis (Rosenbaum, 
Gertner, & Leibel, 1989). In skeletal muscle, GH shifts sub-
strate metabolism from glucose to lipid oxidation (Nellemann 
et al., 2014). This is linked to decreased pyruvate dehydroge-
nase (PDH) activity, which reduces the utilization of glucose 
intermediates for energy production (Nellemann et al., 2014).
Lipid may accumulate in skeletal muscle if the supply 
of lipid intermediates exceeds the capacity or demand for 
its oxidation (Koves et al., 2008). The content of this in-
tramyocellular lipid (IMCL) is associated with insulin resis-
tance in sedentary subjects and type 2 diabetes (Krssak et 
al., 1999; Pan et al., 1997; Shulman, 2014). IMCL primarily 
consists of TAGs, which are synthesized from the esterifica-
tion of fatty acids (FA) and glycerol within skeletal muscle 
(Bonen, Parolin, et al., 2004; Schwarz, Neese, Turner, Dare, 
& Hellerstein, 1995). IMCL content depends on continu-
ous FA uptake since de novo lipogenesis is non‐existent in 
skeletal muscle, wherefore the TAG content in skeletal mus-
cle increases during prolonged fasting with enhanced lipid 
turnover (Stannard et al., 2002). The uptake of FA for TAG 
synthesis in myocytes is facilitated by FA transport proteins, 
binding proteins, and translocase proteins (Glatz, Luiken, & 
Bonen, 2010). The TAG is stored close to the mitochondria 
in lipid droplets formed in the endoplasmic reticulum (ER) 
and these lipid droplets compose a readily available energy 
source (Hoppeler, 1986; Martin & Parton, 2006; Shaw, Jones, 
& Wagenmakers, 2008; Thiam, Farese, & Walther, 2013).
In response to an energy demand, TAG is hydrolyzed 
to FA and glycerol in a process termed lipolysis (Nielsen, 
Jessen, Jorgensen, Moller, & Lund, 2014). Carnitine‐acyl-
carnitine translocase (CACT) facilitates transport of FA into 
the mitochondria for β‐oxidation where carnitine acts as a 
carrier of FA across the mitochondrial membrane (Hoppel 
& Genuth, 1980). Acylcarnitines are also transported across 
the cell membrane via the OCTN2 transporter in a concen-
tration‐dependent manner (Pochini, Oppedisano, & Indiveri, 
2004), and an increase in plasma acylcarnitine can indicate 
incomplete β‐oxidation at a whole‐body level (Hoppel & 
Genuth, 1980; Koves et al., 2008). Degradation of FA to di-
carboxylic acids through ω‐oxidation in the ER only accounts 
for a small part of FA oxidation during normal conditions, 
but may constitute a larger fraction during conditions of in-
complete or exhaustive β‐oxidation such as fasting (Wanders, 
Komen, & Kemp, 2011). In addition to its role as a substrate 
for oxidation, FA are ligands for the peroxisome proliferator‐
activated receptor (PPAR) subfamily of transcription factors, 
which regulate expression of proteins in β‐oxidation (Varga, 
Czimmerer, & Nagy, 2011).
Several lines of evidence suggest that GH directly regulates 
skeletal muscle lipid metabolism and IMCL content. Exogenous 
GH administration to healthy subjects increases IMCL content 
(Krag et al., 2007), whereas treatment of GH excess with a 
specific GH antagonist (GHA) reduces IMCL (Madsen et al., 
2012). To test the hypothesis that GH regulates lipolysis and 
IMCL deposition during fasting, we investigated obese but 
otherwise healthy subjects during prolonged fasting with and 
without GHA. Obese subjects were chosen because they have 
higher FA fluxes during fasting compared to lean subjects (Bak 
et al., 2016). The outcomes were IMCL content, protein levels 
in muscle of key regulators of lipid metabolism, and relative 
changes in the plasma metabolome assessed by non‐targeted 
metabolomics.
2 |  METHODS
2.1 | Ethical approval
The study was approved by the Central Denmark Region 
Scientific Ethics Committee (1‐10‐72‐318‐14), conducted in 
accordance with the Declaration of Helsinki II and reported 
at www.clini caltr ials.gov (NCT02500095). Written consent 
was obtained from all subjects after appropriate deliberation 
time prior to oral and written information.
2.2 | Subjects and study design
Data about study design and subjects characteristics have 
been published previously (Pedersen et al., 2017). In short, 
nine healthy overweight and obese men with a median age of 
24 years (range: 20–32) and a mean body mass index (BMI) of 
30 ± 1.1 kg/m2 were included in the study. The subjects were 
studied thrice separated by at least 4 weeks in a randomized, 
placebo‐controlled crossover design: (a) During an overnight 
fast (12 hr) (“CTRL”), (b) during 72‐hr fasting and placebo 
(“FAST”), and (c) during 72  hr of fasting in combination 
with GHA (pegvisomant) (“FAST  +  GHA”). Pegvisomant 
(SOMAVERT 20  mg; Pfizer, New York City, NY) or pla-
cebo (saline) was injected subcutaneously thrice during 
FAST + GHA: (a) 72 hr prior to initiation of the fasting pe-
riod, (b) at the beginning of fasting, and (c) after completion 
of 48 hr of the fasting period. Each study day consisted of a 
non‐insulin stimulated (“basal”) period from t = 0–240 min 
followed by a 2‐hr hyper‐insulinemic euglycemic clamp 
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(HEC) (t = 240–360 min). Insulin was infused at a rate of 
40 mU/m2 body surface area/min during the HEC (Insulin; 
ACTRAPID; Novo‐Nordisk, Copenhagen, Denmark), which 
increased mean [Confidence interval (CI)] insulin levels 
(pmol/l) to 297 [231;382] (CTRL), 254 [177;364] (FAST) 
and 350 [267;460] (FAST + GHA) during steady state glu-
cose infusion rates.
2.3 | Magnetic resonance spectroscopy  
(1H‐MRS)
On all three occasions, skeletal muscle lipid content was 
measured using 1H magnetic resonance spectroscopy (1H‐
MRS) techniques with a Signa Excite 1.5 Tesla twin‐speed 
scanner (GE Medical Systems, GE Healthcare, Milwaukee, 
WI), as previously described (Moller, Stodkilde‐Jorgensen, 
Jensen, & Jorgensen, 2008). Lipid content was quantified 
in a 2 × 2 × 2 cm3 voxel positioned in the largest cross‐sec-
tional area of the left tibialis anterior muscle and separated 
into IMCL and extramyocellular lipid (EMCL) content. 
1H‐MRS was performed during 12‐hr fasting (CTRL) and 
for practical reasons during 48‐hr fasting instead of 72h 
fasting (FAST and FAST  +  GHA). The area of interest 
was identified using an oblique plane T1‐weighted gradi-
ent echo pulse sequence (repetition time (TR) = 600 ms; 
echo time (TE) = 14 ms; number of excitations (NEX) = 
1). 1H‐MRS of the skeletal muscle was performed using 
a water suppressed point‐resolved spectroscopy sequence 
(TR  =  2000  ms; TE  =  30  ms; NEX  =  8), which gener-
ated spectra with a mean  ±  SE full width at half maxi-
mum on 11.3 ± 0.15 Hz. The spectra were analyzed using 
the LCModel software package (version 6.2; Dr Stephen 
Provencher) by means of a muscle spectroscopy fitting 
model. The data processing provided an estimate of the lipid 
to water ratio in the tissue within the voxel (Provencher, 
1993). IMCL and EMCL are presented as the ratio (%) of 
signal (AU) from lipid to the total signal (lipid + water). 
The spectrum from FAST + GHA was excluded from the 
analysis in one subject due to a low quality of the spectrum. 
The fitted model based on this excluded spectrum had a SD 
of 20, which was well above the overall mean [CI] SD of 
4.3 [2.9; 5.6].
2.4 | Muscle tissue and PDHa activity
Muscle tissue biopsies were obtained under sterile conditions 
using local anesthesia at t  =  60 and t  =  270  min. Muscle 
biopsies were obtained from musculus vastus lateralis of the 
quadriceps muscle with a Bergström cannula and snap‐fro-
zen in liquid nitrogen. All biopsies were stored at − 80 ˚C. 
8–15  mg of muscle tissue was subsequently chipped from 
each biopsy for PDHa activity analysis. The activity of the 
active form of PDH (PDHa) was determined in vitro using 
a radioisotopic assay as previously described (Cederblad, 
Carlin, Constantin‐Teodosiu, Harper, & Hultman, 1990; 
Constantin‐Teodosiu, Cederblad, & Hultman, 1991; Putman 
et al., 1993) after homogenizing of the muscle tissue on ice 
for 50 s using a micro glass homogenizer (Kontes) and quick 
freezing the samples (<15 s) in liquid nitrogen.
2.5 | Metabolomics
Non‐targeted metabolomics was performed in plasma ob-
tained at t  =  0  min at all three occasions. Plasma samples 
were analyzed by Metabolon Inc. (Morrisville, NC) as pre-
viously described (Evans, DeHaven, Barrett, Mitchell, & 
Milgram, 2009). Briefly, metabolites were separated using 
ultrahigh performance liquid chromatography‐tandem mass 
spectroscopy (UPLC‐MS/MS), which provided information 
on mass to charge, retention time, and fragment ion spectra. 
These data were used to detect metabolites via an in‐house 
chemical library and for quantification of relative changes in 
metabolites (fold changes).
2.6 | Western blot analysis
Approximately 5 mg of freeze‐dried muscle tissue was prepared 
for the western blot analysis using the same protocol and equip-
ment as previously described (Moller et al., 2015). Quantification 
of stain‐free blots was used to control for equal loading and for 
total protein normalization as previously reported (Gurtler et 
al., 2013). Antibodies (Ab) against the following proteins were 
purchased from Cell Signaling Technology (Danvers, MA; 
numbers in parentheses indicate catalog numbers): Cytochrom 
c (rabbit, pAb, 4272), succinate dehydrogenase subunit A 
(SDHA) (rabbit, mAb, 11998), voltage‐dependent anion chan-
nel (VDAC) (rabbit, mAb, 4661), PDH‐E1α (rabbit, mAb, 
3205), and from Proteintech (Rosemont, IL): Cluster of differ-
entiation 36 (CD36) (mouse, mAb, 66395‐1‐Ig).
2.7 | Extraction of RNA and quantitative 
PCR for mRNA analysis
RNA was extracted using TRIzol (Gibco BRL, Life 
Technologies, Roskilde, Denmark) and the PCRs were 
performed in duplicate using LightCycler SYBR Green 
master mix (Roche Applied Science) in a LightCycler 480 
(Roche Applied Science) as previously described (Madsen 
et al., 2012; Vendelbo et al., 2012). The following primer 
pairs were designed: fatty acid binding protein 4 (FABP4): 
GCAGATGACAGGAAAGTCAAGAGC and TCTGCACA 
TGTACCAGGACACC, length = 64 base pair (bp). Carnitine 
palmitoyl transferase Iα (CPT‐1): TTATCAACAAGCCAG 
ACCCC and TATAATCCCCGTCTCAGGGC, length  =   
195 bp. CPT‐1β: CTCCTTTCCTTGCTGAGGTG and TCTCG 
CCTGCAATCATGTAG, length = 177 bp. Angiopoietin‐like 
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4 (ANGPTL4): TAGTCCACTCTGCCTCTCCC and 
GAGATGGCCCAGCCAGTT, length = 122 bp. Uncoupling 
protein 2 (UCP2): CCTCATGACAGATGACCTCC and 
TGTATCTCGTCTTGACCACG, length = 104 bp. Glucose 
transporter 4 (GLUT4): CCCCATTCCTTGGTTCATCG 
and ATAGCCTCCGCAACATACTGG, length  =  135   
bp. Nuclear respiratory factor 1 (NRF1): TCCATCTAT 
CCGGAAGAGGCAAC and TCTAACGTGGCTCGAAGT 
TTCCG, length  =  60  bp. PPARα: CAGGAAAGGCCAG 
TAACAATCCAC and CAGCGTCTTCTCAGCCATACAC, 
length = 74bp. PPARδ: TCCTTCCAGCAGCTACACAGAC 
and ATCTGCAGTTGGTCCAGCAGTG, length  =  69bp. 
PPARγ: GTGGCCGCAGATTTGAAAGAA and CCATTA 
CGGAGAGATCCACGG, length = 162 bp. Peroxisome pro- 
liferator‐activated receptor gamma coactivator 1α (PGC‐1α): 
TTGAAGAGCGCCGTGTGATT and TGTCTCCATCA 
TCCCGCAGAT, length  =  129  bp. Pyruvate dehydroge-
nase kinase 4 (PDK4): ATTTAAGAATGCAATGCGGGC 
and GCGGTCAATAATTCTCAGGG, length  =  151  bp. 
The housekeeping gene, β2 microglobulin, was amplified 
using: GAGGCTATCCAGCGTACTCC and AATGTCGG 
ATGGATGAAACCC, length = 111 bp. The expression lev-
els of the housekeeping gene were similar between all groups 
and interventions. All primers were from DNA Technology 
(Risskov, Denmark).
2.8 | Body composition
Body composition was estimated during fasting at t = 0 hr and 
t = 72 hr by means of bioelectrical impedance analysis using 
Tanita body composition analyzer BC‐418 (Tokyo, Japan).
2.9 | Statistics
Normal distribution was evaluated by inspection of QQ 
plots of the residuals from the mixed model, and normally 
distributed data are presented as mean ± SE. Non‐normally 
distributed data were logarithmically transformed using the 
“natural logarithm” and presented as geometric mean ± SE 
on a logarithmic scale on graphs, as logarithmic data 
(mean ± SE) on a linear scale on graphs (mRNA data), as 
(geometric) mean + [CI] or as medians (range). All statis-
tical analyses were made using Stata 13 (College Station, 
TX). Statistical comparisons between the study days were 
performed by a mixed effect one‐ or two‐way ANOVA 
with repeated measures to detect possible main effects 
and interactions between interventions (CTRL, FAST, and 
FAST + GHA) and time (non‐insulin stimulation vs. HEC) 
and adjusted for the random order of interventions. Linear 
pairwise comparisons were performed post hoc to compare 
differences between interventions. p values < .05 were con-
sidered statistically significant. Unadjusted values are pre-
sented in tables and graphs.
3 |  RESULTS
3.1 | Fasting reduces lean body mass (LBM) 
and total body water (TBW) independently of 
GHA
Fasting was not associated with a significant reduction in FM 
from t = 0 hr to t = 72‐hr fasting (ΔFM (kg): 0.18 ± 0.43 
[FAST] vs. 0.28 ± 0.27 [FAST + GHA]; p = .34) but was 
associated with a reduction in LBM (ΔLBM (kg) 4.6 ± 0.31 
[FAST] vs. 3.9 ± 0.28 [FAST + GHA]; p < .01) with no effect 
of GHA (p = .07). TBW was reduced during fasting (ΔTBW 
(Kg): 3.4  ±  0.23 [FAST] vs. 2.8  ±  0.21 [FAST  +  GHA]; 
p < .01) without an effect of GHA (p = .06). This led to an in-
creased fat percentage (%) (1.1 ± 0.4 [FAST] vs. 0.8 ± 0.25 
[FAST + GHA]; p < .01) during 72‐hr fasting that was inde-
pendent of GHA (p = .39).
3.2 | Circulating Free FA (FFA), Ketone 
bodies, and GH increase and insulin levels 
decrease during fasting
Plasma concentrations of FFA, 3‐hydroxybutyrate, insulin 
and GH levels have previously been published (Pedersen et 
al., 2017) and are summarized in Table 1.
T A B L E  1  Plasma levels of hormones and metabolites presented as (geometric) mean [CI] at t = 0, 48 and 72‐hr fasting as previous reported 
(Pedersen et al., 2017)
  0 hr 48 hr 72 hr
  FAST FAST+GHA FAST FAST+GHA FAST FAST+GHA
FFA (mmol/l) 0.14 [0.05;0.23] 0.14 [0.09;0.19] 0.67 [0.51;0.83] 0.81 [0.60;1.04] 1.12 [0.90;1.34] 1.28 [1.06;1.50]
3OHB (μmol/l) 15.8 [11.4;20.3] 17.1 [8.0; 26.2] 1,192 [748;1636] 1,186 [672;1699] 2,327 [1598;3056] 2,268 [1659;2876]
GH (ng/ml) 0.05 [0.03;0.09] 0.05 [0.04;0.06] 2.29 [0.54;9.60] 2.66 [1.19;5.95] 0.56 [0.17;1.84] 0.82 [0.23;3.01]
Insulin (pmol/l) 185 [103;334] 161 [97;269] 27 [21;35] 33 [25;44] 31 [22;45] 34 [26;46]
Note: p < .05 for the effect of time (fasting) for all variables. p > .05 for FAST versus FAST + GHA for all variables. 3‐hydroxybutyrate (3OHB). Free fatty acid (FFA).
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3.3 | CD36 Protein content is unaffected by 
prolonged fasting and GHA
Protein expression of CD36 (fatty acids translocase) in skeletal 
muscle was not influenced by either fasting or GHA (Figure 1a).
3.4 | PDHa activity decreases during fasting 
independently of GHA
PDHa activity was measured to quantify the utilization of 
glucose intermediates (pyruvate) from the glycolytic path-
way for oxidation in the citric acid cycle (Putman et al., 
1993). The PDHa activity was reduced by ≈ 55%–60% dur-
ing FAST as well as FAST  +  GHA compared to CTRL 
(p < .01) without an independent effect of GHA (p = .57). 
Noteworthy, insulin stimulation did not affect PDHa activ-
ity during either CTRL, FAST, or FAST + GHA (p = .71) 
(Figure 1b). Reduced PDHa activity was associated with 
increased PDK4 expression (p < .01) without an independ-
ent effect of GHA (p = .78). There was a small decrease in 
PDK4 expression during insulin stimulation independent 
of fasting or GHA (p = .46 for the interaction) (Figure 1c).
3.5 | Fasting increases the mRNA content of 
PPAR‐regulated target genes involved in 
FA oxidation
Prolonged fasting was associated with a GHA‐independent in-
crease in mRNA content of FABP4, CPT‐1α, ANGPTL4, and 
UCP2, whereas the mRNA content of CPT‐1β only increased 
during fasting without GHA (Figure 2a–e). GLUT4 and NRF1 
were unaltered by prolonged fasting and GHA (Figure 2f–G). 
PGC1α, PPARα, PPARδ, and PPARγ mRNA content was also 
unchanged during prolonged fasting (Figure 2i–K).
3.6 | IMCL accumulates during prolonged 
fasting independently of GHA
The relative IMCL content increased ≈75% with FAST 
and FAST  +  GHA compared to CTRL (p  <  .01) with-
out an independent effect of GHA (p = .44) (Figure 3a). 
EMCL was unaffected by both fasting and GHR blockade 
(Figure 3b).
3.7 | Mitochondrial protein content is 
unaltered during fasting
The content of the mitochondrial proteins cytochrome c, 
SDHA, VDAC, and PDH‐E1α did not change in response 
to FAST or FAST + GHA (Figure 4a–d).
3.8 | Prolonged fasting shifts the plasma 
metabolome from glucose to lipid intermediates
3.8.1 | Fasting induces prominent 
medium‐ and long‐chain fatty acid increase
Fasting was associated with a substantial increase in 
lipid intermediates (e.g., myristate, arachidate, and li-
noleate) and a decrease in carbohydrate intermediates 
F I G U R E  1  CD36 protein content, 
PDH activity, and PDK4 expression. (a) 
Geometric mean ± SE for CD36 protein 
content. (b) Mean ± SE for PDHa activity. 
(c) Mean ± SE for log mRNA expression 
of PDK4. N = 9. (d) Stain‐free blot image 
used for total protein normalization of CD36 
(Figure 1a)
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(e.g., glucose, fructose, pyruvate, and glycerate) (Table 
2). Fasting increased medium‐chain FA ≈1.5 times and in-
duced a tripling of long‐chain FA content (p < .05) (Figure 
5a and Table 2). The same effect was observed for poly-
unsaturated and branched‐chain FA (p  <  .05) (Table 2). 
Monoacylglycerols, diacylglycerols, free glycerol, and 
sphingolipids also increased (p <  .05), whereas phospho-
lipids decreased in response to FAST and FAST + GHA 
(Table 2). There was no overall effect of GHA on plasma 
FA metabolite distribution besides the short‐chain FA 
“valerate,” which decreased statistically significant during 
FAST + GHA (Fold change = 0.42; p < .05).
F I G U R E  2  mRNA content of PPAR‐regulated genes and PPARα, β, and γ. (a) Mean ± SE for log mRNA content of FABP4. (b) Mean ± SE 
for log mRNA content of CPT1α. (c) Mean ± SE for log mRNA content of CPT1α. (d) Mean ± SE for log mRNA content of ANGPTL4.  
(e) Mean ± SE for log mRNA content of UCP2. (f) Mean ± SE for log mRNA content of GLUT4. (g) Mean ± SE for log mRNA content of NRF1. 
(h) Mean ± SE for log mRNA content of PGC1α. (i) Mean ± SE for log mRNA content of PPARα. (j) Mean ± SE for log mRNA content of 
PPARβ. (k) Mean ± SE for log mRNA content of PPARγ. 12‐hr fasting (CTRL), 72‐hr fasting (FAST), and 72‐hr fasting + GHA (FAST + GHA). 
N = 9. Not significant (NS). N = 9
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3.8.2 | Fasting is associated with elevated 
levels of intermediates from β‐oxidation and  
ω‐oxidation
The majority of short‐, medium‐, and long‐chain acylcarnitines 
increased significantly (Fold change ≈ 1.5–8) during FAST and 
FAST + GHA (p < .05) indicative of incomplete β‐oxidation 
(Figure 5b and Table 2). This was accompanied by a decrease in 
free plasma carnitine concentrations (p < .05) (Table 2). FAST 
was also associated with a 20‐fold increase in the dicarboxylic 
acid “sebacate” derived from ω‐oxidation, and the hydroxy-
dicarboxylic acid metabolite “3‐hydroxy sebactate,” supporting 
the concept of ω‐oxidation as a rescue pathway during saturated 
β‐oxidation (p < .05) (Figure 5c–d and Table 2). As expected, 
FAST also induced a substantial elevation in ketone body levels 
with a ≈30‐fold and ≈45‐fold increase in circulating acetoac-
etate and 3‐hydroxybutyrate, respectively (p < .05) (Figure 5e 
and Table 2). The lipid metabolite “3‐hydroxybutyryl‐carni-
tine” also increased pronouncedly during FAST independent of 
GHA (p < .05) (Figure 5f).
3.9 | Branched‐chain amino acids 
(BCAA) and sulfur amino acid (SUAA) 
metabolites increase during fasting
The three BCAA leucine, isoleucine, and valine together 
with their downstream metabolites increased during FAST 
(p < .05) without a significant effect of GHA (Figure 5g and 
Table 2). Prolonged fasting was also associated with GHA‐in-
dependent accumulation of several methionine intermediates 
in plasma together with increased levels of α‐ketobutyrate 
and its downstream metabolites 2‐aminobutyrate and 2‐hy-
droxybutyrate (Figure 5h and Table 2).
4 |  DISCUSSION
This study was designed to assess the importance of en-
dogenous GH actions on the intramyocellular lipid content 
and key regulators of lipid metabolism during prolonged 
fasting in obese but otherwise healthy subjects. We did 
not record significant effects of GHA on either of these 
outcomes, which indicates that redundant mechanisms 
promote adipose tissue lipolysis and lipid storage in mus-
cle during prolonged fasting. However, these data do not 
challenge the important role of GH as a regulator of lipid 
metabolism that has been established in studies of GH‐de-
ficient subjects (Norrelund, Djurhuus, et al., 2003) and in 
fasting healthy subjects infused with GH (Norrelund, Nair, 
et al., 2003).
The marked increase in circulating medium‐ and long‐
chain FA, monoacylglycerols, diacylglycerols, and free 
glycerol during prolonged fasting demonstrates an in-
creased supply of lipid intermediates to skeletal muscles. 
This was not associated with increased protein content of 
the fatty acid transporter, CD36, in skeletal muscle. This 
does not preclude increased transport of FAs into muscle, 
since we were only able to measure total CD36 content 
rather than the active proportion of the protein, which is 
translocated to the cell surface (Bonen, Campbell, et al., 
F I G U R E  3  IMCL and EMCL during 
72‐hr fasting. (a) Mean ± SE for the relative 
IMCL content. (b) Mean ± SE for the 
relative EMCL content. (c) Representative 
water‐suppressed point‐resolved 
spectroscopy sequence of the volume of 
interest in musculus tibialis anterior. (d) 
Representative image of an oblique‐plane 
T1‐weighted gradient echo pulse sequences 
with the voxel positioned in a homogeneous 
part of the musculus tibialis anterior. 12‐hr 
fasting (CTRL), 72‐hr fasting (FAST), and 
72‐hr fasting + GHA (FAST + GHA). 
N = 8. Not significant (NS).
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2004). PDH is a key regulator of carbohydrate oxidation, 
and reduced PDHa activity partitions lipid intermediates 
toward oxidation at the expense of carbohydrates (Randle, 
Garland, Hales, & Newsholme, 1963). In accordance, pro-
longed fasting was associated with decreased PDHa activ-
ity, which was not modulated by GHA. In lean subjects, 
administration of exogenous GH reduces PDHa activity in 
skeletal muscle (Nellemann et al., 2014). This is likely a 
consequence of increased lipid oxidation and the associ-
ated elevated acetyl‐CoA/CoA‐ratio (Putman et al., 1993). 
In addition, PDHa activity is negatively regulated by pyru-
vate dehydrogenase kinase 4 (PDK4) (Pilegaard & Neufer, 
2004) which is increased by elevated FA levels (Kelley, 
Mokan, Simoneau, & Mandarino, 1993; Wu, Inskeep, 
Bowker‐Kinley, Popov, & Harris, 1999). In accordance, we 
observed increased PDK4 expression during fasting. We 
did not detected increased PDHa activity during insulin 
stimulation, but a small decrease in PDK4 expression. This 
contrasts observations in lean subjects (Mandarino et al., 
1987). The underlying mechanism is likely higher levels 
of PDK4 in muscle from obese versus lean subjects, and 
the inability of insulin to stimulate PDHa activity suggests 
that insulin resistance in obese individuals can be detected 
also at the level of regulators of substrate metabolism. 
Surprisingly, increased lipolysis and lipid oxidation did not 
result in significant lower FM measured by bioelectrical 
impedance. This could be explained by reduced energy 
expenditure during fasting. However, this study was not 
powered to detect a difference in body composition using 
bioelectrical impedance.
The expression of PPARγ target genes such as FABP 4 
(Desvergne & Wahli, 1999), ANGPTL4 (Rogue, Spire, Brun, 
Claude, & Guillouzo, 2010) as well as UCP2 (Desvergne 
& Wahli, 1999) and CPT‐Iα (Desvergne & Wahli, 1999) 
increased during prolonged fasting as previously reported 
(Rosenbaum et al., 1989; Salomon et al., 1989), which was 
independent of GHA. Noteworthy, CPT‐Iβ expression (the 
muscle isoform) was unchanged during FAST + GHA com-
pared to CTRL, which indicate hampered FA oxidation 
during fasting in the presence of GHR blockade. FABP4 
controls intracellular lipid transport to lipid droplets and to 
the mitochondria. CPT‐I is the rate‐limiting enzyme of FA 
F I G U R E  4  Protein content of 
mitochondrial proteins (a) Geometric 
mean ± SE for cytochrome c. (b) Geometric 
mean ± SE for SDHA. (c) Geometric 
mean ± SE for VDAC. (d) Geometric 
mean ± SE for PDH‐E1α. 12‐hr fasting 
(CTRL), 72‐hr fasting (FAST), and 72‐hr 
fasting + GHA (FAST + GHA). N = 9. 
Not significant (NS). Representative 
western blots are for CTRL, FAST, and 
FAST + GHA are shown below the figures. 
N = 9. (e) Stain‐free blot image used for 
total protein normalization of Cytochrom 
C, SDHA, and VDAC (Figure 4a–c). (f) 
Stain‐free blot image used for total protein 
normalization of PDH (Figure 4d)
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T A B L E  2  Selected metabolites during CTRL, FAST, and FAST + GHA
Metabolites Fold change Repeated Measures ANOVA
Group Specific metabolites
FAST
CTRL
FAST + GHA
CTRL
FAST + GHA
FAST
FAST/CTRL
FAST + GHA/
CTRL
FAST + GHA/
FAST
p value Q value p value Q value p value Q value
Carbohydrate Glucose 0.81 0.84 1.05 .00 0.00 .00 0.00 .21 1.00
Pyruvate 0.84 0.80 0.95 .09 0.03 .03 0.01 .59 1.00
Glycerate 0.88 0.81 0.92 .03 0.01 .00 0.00 .16 1.00
Fructose 0.48 0.47 0.98 .00 0.00 .00 0.00 .79 1.00
Mannitol/sorbitol 0.33 0.36 1.10 .00 0.00 .01 0.00 .67 1.00
Short‐chain fatty 
acid
Valerate 0.81 0.42 0.51 .22 0.07 .01 0.00 .11 1.00
Medium‐chain 
fatty acid
Caprylate 1.48 1.66 1.12 .00 0.00 .00 0.00 .29 1.00
Caprate 1.64 1.53 0.93 .00 0.00 .00 0.00 .40 1.00
Laurate 1.80 1.98 1.10 .00 0.00 .00 0.00 .35 1.00
5‐Dodecenoate 2.99 3.37 1.13 .00 0.00 .00 0.00 .74 1.00
Long‐chain fatty 
acid
Myristate 2.51 2.93 1.17 .00 0.00 .00 0.00 .23 1.00
Myristoleate 2.26 2.55 1.13 .00 0.00 .00 0.00 .59 1.00
Pentadecanoate 2.06 2.34 1.14 .00 0.00 .00 0.00 .24 1.00
Palmitate 2.45 2.71 1.11 .00 0.00 .00 0.00 .31 1.00
Palmitoleate 2.60 3.23 1.24 .00 0.00 .00 0.00 .28 1.00
Margarate 3.06 3.34 1.09 .00 0.00 .00 0.00 .50 1.00
Stearate 2.23 2.27 1.02 .00 0.00 .00 0.00 .86 1.00
Arachidate 2.12 2.32 1.09 .00 0.00 .00 0.00 .66 1.00
Eicosenoate 3.55 3.83 1.08 .00 0.00 .00 0.00 .59 1.00
Oleate/vaccenate 2.60 2.80 1.08 .00 0.00 .00 0.00 .51 1.00
Polyunsaturated 
fatty acid
(n3 and n6)
Stearidonate 1.24 1.57 1.26 .11 0.04 .01 0.00 .25 1.00
Eicosapentaenoate 1.81 2.03 1.13 .00 0.00 .00 0.00 .60 1.00
Docosapentaenoate 2.50 2.82 1.13 .00 0.00 .00 0.00 .39 1.00
Docosahexaenoate 1.81 1.93 1.07 .00 0.00 .00 0.00 .66 1.00
Linoleate 2.56 2.88 1.12 .00 0.00 .00 0.00 .29 1.00
Arachidonate 1.91 2.07 1.09 .00 0.00 .00 0.00 .41 1.00
Adrenate 2.72 3.01 1.10 .00 0.00 .00 0.00 .39 1.00
Fatty acid, 
branched
13‐Methylmyristate 1.94 2.15 1.11 .00 0.00 .00 0.00 .65 1.00
15‐Methylpalmitate 2.27 2.40 1.06 .00 0.00 .00 0.00 .72 1.00
17‐Methylstearate 2.29 1.89 0.83 .00 0.00 .00 0.00 .04 1.00
Fatty acid, 
dicarboxylate
Adipate 9.09 7.76 0.85 .00 0.00 .00 0.00 .43 1.00
Sebacate (decanedioate) 19.79 15.96 0.81 .00 0.00 .00 0.00 .62 1.00
Dodecanedioate 16.59 14.08 0.85 .00 0.00 .00 0.00 .83 1.00
Tetradecanedioate 12.05 10.68 0.89 .00 0.00 .00 0.00 .90 1.00
Hexadecanedioate 10.09 9.26 0.92 .00 0.00 .00 0.00 .84 1.00
Octadecanedioate 4.49 3.89 0.87 .00 0.00 .00 0.00 .54 1.00
Fatty acid, amino 2‐Aminoheptanoate 0.39 0.47 1.22 .00 0.00 .00 0.00 .03 1.00
2‐Aminooctanoate 0.61 0.64 1.05 .01 0.00 .02 0.01 .64 1.00
Fatty acid 
synthesis
Malonate 1.20 1.58 1.31 .43 0.12 .02 0.01 .08 1.00
(Continues)
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Metabolites Fold change Repeated Measures ANOVA
Group Specific metabolites
FAST
CTRL
FAST + GHA
CTRL
FAST + GHA
FAST
FAST/CTRL
FAST + GHA/
CTRL
FAST + GHA/
FAST
p value Q value p value Q value p value Q value
Fatty acid 
metabolism
(also BCAA 
metabolism)
Butyrylcarnitine 1.23 1.22 0.99 .02 0.01 .03 0.01 .82 1.00
Butyrylglycine 1.51 1.53 1.01 .04 0.02 .04 0.01 .97 1.00
Propionylcarnitine 0.73 0.66 0.91 .00 0.00 .00 0.00 .17 1.00
Propionylglycine 0.24 0.23 0.96 .00 0.00 .00 0.00 .85 1.00
Methylmalonate 0.55 0.57 1.04 .00 0.00 .00 0.00 .55 1.00
Fatty acid 
metabolism
(Acyl Glycine)
Hexanoylglycine 2.26 2.19 0.97 .00 0.00 .00 0.00 .67 1.00
N‐Palmitoylglycine 1.58 1.50 0.94 .00 0.00 .00 0.00 .77 1.00
Fatty acid 
metabolism
(Acyl Carnitine)
Acetylcarnitine 3.79 3.39 0.89 .00 0.00 .00 0.00 .24 1.00
3‐Hydroxybutyrylcarnitine 73.64 63.05 0.86 .00 0.00 .00 0.00 .56 1.00
Hexanoylcarnitine 2.64 2.68 1.01 .00 0.00 .00 0.00 .99 1.00
Octanoylcarnitine 2.40 2.50 1.04 .00 0.00 .00 0.00 1.00 1.00
Decanoylcarnitine 2.56 2.70 1.05 .00 0.00 .00 0.00 .79 1.00
Laurylcarnitine 4.31 3.94 0.92 .00 0.00 .00 0.00 .73 1.00
Myristoylcarnitine 5.46 4.90 0.90 .00 0.00 .00 0.00 .49 1.00
Palmitoylcarnitine 2.16 2.12 0.98 .00 0.00 .00 0.00 .72 1.00
Palmitoleoylcarnitine 4.95 4.78 0.97 .00 0.00 .00 0.00 .95 1.00
Linolenoylcarnitine 2.42 2.66 1.10 .00 0.00 .00 0.00 .36 1.00
Oleoylcarnitine 2.36 2.45 1.04 .00 0.00 .00 0.00 .51 1.00
Myristoleoylcarnitine 6.63 6.68 1.01 .00 0.00 .00 0.00 .88 1.00
Suberoylcarnitine 9.47 8.52 0.90 .00 0.00 .00 0.00 .36 1.00
Docosahexaenoylcarnitine 1.94 1.59 0.82 .00 0.00 .01 0.00 .18 1.00
Margaroylcarnitine 2.26 2.01 0.89 .00 0.00 .00 0.00 .33 1.00
Carnitine 
metabolism
Deoxycarnitine 0.98 1.00 1.02 .74 0.19 .82 0.20 .92 1.00
Carnitine 0.78 0.77 0.99 .00 0.00 .00 0.00 .85 1.00
Ketone bodies Acetoacetate 30.35 31.84 1.05 .00 0.00 .00 0.00 .78 1.00
3‐Hydroxybutyrate 44.97 42.03 0.93 .00 0.00 .00 0.00 .91 1.00
Fatty acid, 
monohydroxy
3‐Hydroxyhexanoate 5.54 5.25 0.95 .00 0.00 .00 0.00 .75 1.00
3‐Hydroxyoctanoate 5.63 5.26 0.93 .00 0.00 .00 0.00 .98 1.00
3‐Hydroxydecanoate 4.03 4.22 1.05 .00 0.00 .00 0.00 .92 1.00
3‐Hydroxysebacate 25.04 21.48 0.86 .00 0.00 .00 0.00 .72 1.00
Fatty acid, 
dihydroxy
12.13‐Dihome 0.77 0.85 1.12 .04 0.01 .14 0.04 .48 1.00
9.10‐Dihome 1.57 1.62 1.03 .01 0.00 .00 0.00 .77 1.00
Monoacylglycerol 1‐Linoleoylglycerol 1.27 1.30 1.02 .13 0.04 .06 0.02 .67 1.00
1‐Arachidonylglycerol 1.36 2.17 1.60 .01 0.01 .00 0.00 .05 1.00
1‐Docosahexaenoylglycerol 1.55 1.96 1.27 .02 0.01 .00 0.00 .27 1.00
Diacylglycerol Linoleoyl‐arachidonoyl‐
glycerol
2.84 2.95 1.04 .00 0.00 .00 0.00 .94 1.00
Linoleoyl‐docosahexae-
noyl‐glycerol
4.44 3.52 0.79 .00 0.00 .00 0.00 .25 1.00
Palmitoyl‐arachidonoyl‐ 5.25 6.47 1.23 .00 0.00 .00 0.00 .34 1.00
Palmitoyl‐docosahexae-
noyl‐glycerol
4.88 4.16 0.85 00 0.00 .00 0.00 .31 1.00
T A B L E  2  (Continued)
(Continues)
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oxidation, as CPT‐I enables influx of long‐chain FA to the 
mitochondria, and ANGPTL4 is associated with increased 
lipid mobilization and FA oxidation (Mandard et al., 2006). 
Increased expression of UCP2 has been linked to protec-
tion of mitochondria during fatty acid β‐oxidation (Azzu, 
Jastroch, Divakaruni, & Brand, 2010; Patterson, Shah, 
Matsubara, Krausz, & Gonzalez, 2012). Lipid intermediates 
can act as activators of PPAR‐regulated gene transcription 
(Varga et al., 2011), and this mechanism is therefore likely to 
mediate the transcriptional effects independently of canoni-
cal GHR‐signaling. Thus, the combined activation of PPAR‐
regulated genes increases the capacity for lipid oxidation 
(Varga et al., 2011) and may play a dominant role in the met-
abolic adaptation to fasting in muscle tissue. The increases 
Metabolites Fold change Repeated Measures ANOVA
Group Specific metabolites
FAST
CTRL
FAST + GHA
CTRL
FAST + GHA
FAST
FAST/CTRL
FAST + GHA/
CTRL
FAST + GHA/
FAST
p value Q value p value Q value p value Q value
Glycerolipid 
metabolism
Glycerol 2.15 3.09 1.44 .00 0.00 .00 0.00 .06 1.00
Glycerol 3‐phosphate 1.06 0.93 0.88 .68 0.18 .48 0.13 .27 1.00
Phospholipid 
metabolism
1‐Palmitoleoyl−2‐linole-
noyl‐GPC
0.23 0.23 0.97 .00 0.00 .00 0.00 .57 1.00
1.2‐Dilinoleoyl‐GPC 0.26 0.26 0.99 .00 0.00 .00 0.00 .95 1.00
Sphingomyelin 3.04 3.05 1.00 .00 0.00 .00 0.00 .83 1.00
Fatty acid 
metabolism
(Acyl Choline)
Palmitoylcholine 0.60 0.77 1.29 .09 0.03 .37 0.11 .38 1.00
Oleoylcholine 0.51 0.62 1.21 .04 0.01 .12 0.04 .54 1.00
Linoleoylcholine 0.41 0.52 1.27 .01 0.00 .05 0.02 .38 1.00
Stearoylcholine 0.36 0.46 1.27 .02 0.01 .07 0.02 .59 1.00
Fatty acid 
metabolism
(Acyl Glutamine)
Hexanoylglutamine 22.62 21.93 0.97 .00 0.00 .00 0.00 .79 1.00
Leucine, isoleucine 
and
valine metabolism
Leucine 1.60 1.50 0.94 .00 0.00 .00 0.00 .15 1.00
Isovalerate 1.53 1.51 0.99 .00 0.00 .00 0.00 .88 1.00
Isovalerylglycine 1.49 1.36 0.91 .04 0.01 .11 0.04 .59 1.00
Beta‐hydroxyisovalerate 1.61 1.90 1.18 .00 0.00 .00 0.00 .30 1.00
alpha‐hydroxyisovalerate 3.09 3.34 1.08 .00 0.00 .00 0.00 .65 1.00
Isoleucine 1.67 1.63 0.98 .00 0.00 .00 0.00 .52 1.00
2‐Methylbutyrylcarnitine 1.39 1.23 0.89 .02 0.01 .27 0.08 .20 1.00
2‐Hydroxy−3‐methyl-
valerate
3.38 3.51 1.04 .00 0.00 .00 0.00 1.00 1.00
3‐Hydroxy−2‐ethylpro-
pionate
2.24 2.35 1.05 .00 0.00 .00 0.00 .75 1.00
Valine 1.39 1.31 0.94 .00 0.00 .00 0.00 .16 1.00
Methionine, 
cysteine,
and taurine 
metabolism
Methionine 0.91 0.88 0.97 .12 0.04 .05 0.02 .65 1.00
Methionine sulfone 1.33 1.44 1.08 .02 0.01 .00 0.00 .52 1.00
Methionine sulfoxide 0.78 0.79 1.01 .00 0.00 .00 0.00 1.00 1.00
Cystathionine 0.73 0.64 0.88 .12 0.04 .10 0.03 .89 1.00
Alpha‐ketobutyrate 3.57 3.32 0.93 .00 0.00 .00 0.00 .53 1.00
2‐Aminobutyrate 2.44 2.36 0.96 .00 0.00 .00 0.00 .47 1.00
Cysteine 1.24 1.00 0.81 .06 0.02 .99 0.24 .06 1.00
Cystine 1.13 1.10 0.98 .52 0.14 .50 0.14 .98 1.00
S‐Methylcysteine 0.95 1.07 1.12 .95 0.23 .37 0.11 .40 1.00
Taurine 1.27 1.27 1.00 .03 0.01 .03 0.01 .93 1.00
2‐Hydroxybutyrate/2‐hy-
droxyisobutyrate
5.57 5.37 0.96 0.00 0.00 .00 0.00 .66 1.00
Threonine Threonine 0.69 0.68 0.99 .00 0.00 .00 0.00 .86 1.00
Note: Fold changes (FAST vs. CTRL, FAST + GHA vs. CTRL, and FAST + GHA vs. FAST) of specific metabolites grouped into different pathways of the metabo-
lism are provide together with the P values and Q values of the repeated measures ANOVA. Branched‐chain amino acids (BCAA). N = 9
T A B L E  2  (Continued)
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in PPAR‐regulated genes are compatible with transcriptional 
regulation of β‐oxidation in skeletal muscle. In contrast, we 
did not find evidence of altered PPARα, β or γ expression. 
Likewise, we observed unaltered PPARγ coactivator 1‐α 
(PGC‐1α) activity during prolonged fasting in obese sub-
jects as both the PGC‐1α, GLUT4,and NRF1 mRNA content 
(Finck & Kelly, 2006) and the protein content of several mi-
tochondrial proteins were preserved.
We chose to study obese but otherwise healthy subjects 
due to their higher FA fluxes during fasting as compared 
to lean subjects (Bak et al., 2016). The physiological re-
sponse to prolonged fasting involves IMCL accumulation in 
lean subjects, and the present results demonstrate that this 
also occurs to the same degree in obese subjects. In con-
trast, the decrease in insulin sensitivity during 72 hr fasting 
is more pronounced in lean subjects (Pedersen et al., 2017; 
Vendelbo et al., 2012). Of note, previous studies have shown 
that IMCL starts to accumulate during ≈24‐hr fasting and 
continues until at least 120‐hr fasting in lean (Vendelbo 
et al., 2012; Wietek et al., 2004). Accumulation of IMCL 
therefore appears to be a physiological adaption to fasting 
independent of body composition and without direct cor-
relation to the level of insulin resistance. In that sense, it is 
in accordance with observations of increased IMCL levels 
in endurance‐trained athletes with high insulin sensitivity 
(Goodpaster, He, Watkins, & Kelley, 2001). This suggests 
that the increase in IMCL during prolonged fasting per se is 
not directly linked to insulin resistance. The present obser-
vation that there is no effect of prolonged fasting on EMCL 
in obese but otherwise healthy subjects is in agreement with 
data in lean subjects (Stannard et al., 2002). EMCL consti-
tutes a quantitatively larger lipid pool than IMCL for which 
reason a longer fasting period may be required to induce de-
tectable changes.
F I G U R E  5  Plasma metabolite 
concentrations measured at t = 0 min 
during 12‐hr fasting, 72‐hr fasting alone, 
and 72‐hr fasting with concomitant 
pegvisomant administration. (a–h) Data 
for each metabolite are presented as box 
and whiskers plot (maximum value, 
75th percentile, median, 25th percentile, 
minimum value). 12‐hr fasting (CTRL), 72‐
hr fasting (FAST), and 72‐hr fasting + GHA 
(FAST + GHA). N = 9
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The increased availability of lipid intermediates during 
prolonged fasting provides substrates for ketogenesis, 
which is in accordance with the observation that plasma 
levels of ketone bodies increased by >30‐fold in our study. 
This lipolytic and ketogenic effect can be stimulated by ex-
ogenous GH administration during fasting in GH‐deficient 
patients (Norrelund, Djurhuus, et al., 2003), but in this 
study of obese but otherwise healthy subjects, the increase 
in lipid intermediates and ketone bodies was independent 
of GHA. This discrepancy could be due to the fact that obe-
sity is associated with a blunted elevation in GH secretion 
and action in response to fasting (Riedel, Hoeft, Blum, von 
zur Muhlen, & Brabant, 1995). It is also possible that the 
magnitude of GH blockade, which we obtained, was in-
complete as regards lipid metabolism, even though GHA in 
the present study had a significant impact on serum IGF‐I 
levels [194.6  ng/ml (saline) vs. 162.6  ng/ml (GHA)] and 
endogenous glucose production (Pedersen et al., 2017). 
Indeed, we did record sporadic STAT5 phosphorylation 
in muscle during GHA in the present study (Pedersen et 
al., 2017) which could represent GH signaling. One could 
speculate that bio‐distribution of pegvisomant reduces the 
accessibility to the receptors in muscle and adipose tissue 
compared to liver tissue, which could explain the hepatic 
effects of GHA in the presence of only minor effects in 
muscle and adipose tissue.
Ketone bodies can serve as substrates for oxidation in skel-
etal muscle (Randle et al., 1963). The metabolomics analysis 
performed in this study was conducted as a non‐targeted in-
vestigation and we were therefore only able to detect relative 
changes in metabolites. This limits firm conclusions, but the 
pronounced increase in circulating “3‐hydroxybutyryl‐carni-
tine” is compatible with ketone body metabolism in skeletal 
muscle (Soeters et al., 2012). Our subjects did not perform 
physical activities during the fasting period, and fasting per 
se does not lead to energy deprivation in muscle (Vendelbo et 
al., 2012; Wijngaarden, Zon, Dijk, Pijl, & Guigas, 2013). The 
observed increases in “3‐hydroxybutyryl‐carnitine” and other 
acylcarnitines suggest that energy supply exceeds the resting 
energy requirements during prolonged fasting. Our findings 
are in accordance with data from metabolomics on skeletal 
muscle during prolonged fasting (Bak et al., 2018). In humans, 
the maximal capacity for β‐oxidation can be reached during 
intravenous lipid infusion in human subjects (Gormsen et al., 
2007). ω‐oxidation constitutes a rescue pathway for FA oxida-
tion during exhaustive lipid catabolism (Wanders et al., 2011) 
and the observed increase in dicarboxylic acids and their down-
stream metabolites, which can be generated during ω‐oxida-
tion, provide further support for saturated β‐oxidation during 
prolonged fasting. Yet, the concept of saturated β‐oxidation re-
mains speculative. Acylcarnitines and “3‐hydroxybutyryl‐car-
nitine” are associated with insulin resistance, and they may act 
in synergy with BCAA to suppress insulin actions (Newgard, 
2012). We demonstrated that acylcarnitines and BCAA also 
increase in relation to fasting‐induced insulin resistance. Our 
observations of IMCL accumulation and ω‐oxidation indicate 
that plasma acylcarnitines increase because of excess energy 
availability from lipolysis.
In conclusion, fasting induces a selective use of lipids as 
fuel in skeletal muscle. The massive supply of lipid interme-
diates is partitioned to lipid oxidation and this may saturate 
the capacity for β‐oxidation. Lipids also accumulate in skele-
tal muscle during fasting, which is not modified significantly 
by GHA, which could indicate either insufficient GH block-
ade or the existence of redundant mechanisms to ensure lipid 
mobilization. This also suggests that lipid accumulation in 
skeletal muscle during fasting is driven by an increased sup-
ply that exceeds the demand for lipid utilization in obese sub-
jects. New studies are needed to establish the role of GH on 
skeletal muscle lipid metabolism during fasting and to clarify 
the concept of saturable β‐oxidation.
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